Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tricky/old news, they are moving to Earnshaw St at the top of Oxford St
I can’t remember the last bad news here.
The Blenrep phase 3 DREAMM-8 trial met its primary endpoint of progression free survival with the regimen shown to significantly extend the time to disease progression or death versus the existing standard of care. The dataset has been unblinded early on the advice of its independent data monitoring committee. The readout comes just one month after GSK announced positive results from the DREAMM-7 trial. Armed with successes on two phase 3 trials GSK will be in discussion with the FDA about the reintroduction of the drug in the US.
Analysts at Citi anticipate risk adjusted Blenrep sales of £2.5bn in 2035.
No wonder GSK shares are up over 18% since the beginning of the year.
I'm hovering on the sell button TBH. Similar buy in average but need to shift a stack before an imminent mortgage renewal rate increase and the CGT reduction. A bird in the hand and all that.....
End of Tax year 23-24 on 05.04.24
HMRC are to reduce Capital Gains Tax allowance.
Why not rethink!!!
To break a blank posting day, when Glaxo has made a nice move up beyond £17 - gone well since my last purchase at £14 - have a below £13 average - not yet a high enough valuation to contemplate any sales.
GSK has sold GSK House in Brentford to Hadley Property Group.
Good news OR 'not'
I bought in at 13.28
More to go.
https://www.gsk.ai/
This should not have a negative impact on the SP in any way. GSK had the same results in the 2nd year. This was all about being first to Market which GSK was. People don’t like changing medication once something works for them. It’s then all about building on this by gaining approval for younger ages which GSK is also well ahead of the competition on.
It probably has to do with Pfizer's announcement from yesterday, threatening GSK's dominance so far here.
Pfizer says its RSV shot is protective through a second year
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-its-rsv-shot-is-protective-through-second-year-2024-02-29/
Since you ask, Badgernator, I have only kept a small part, reinvesting some in Puretech Health (Doubling this holding) and diversifying into 'safe' emerging fund Utilico Emerging Markets. All the best!
It's slowly drifting down and struggles to pass £17 resistance. I mean, is it really the Zantac case to hold this share down? historical defensive stock, solid company, good results, fairly decent dividend ...it should hoovering around £20 at least :-(
Good luck olda couldn’t hold for the 1750 eh? I obviously think selling was a mistake as I still hold. Any plans for the money? I’m hoping gsk has the wind in its sails now. I’m hoping they they know what they are doing settling these cases. Once the Zantac litigation is over I can’t see what will hold this back from getting the same rating as it’s peers.
....close to £17 and I think ex-div. Small profit but releases a lot of cash. Good luck to all who hang on.
According to that, it could also go down. I have come to expect GSK to do both.
9.23% since 4th January 2024. Appears to be plenty more to come.
"The 20 analysts offering 12 month price targets for GSK plc have a median target of 1,770.00, with a high estimate of 2,490.00 and a low estimate of 1,200.00. The median estimate represents a 5.84% increase from the last price of 1,672.40."
GSK reports positive results from gonorrhoea treatment trial.
GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.
https://www.investments.halifax.co.uk/research-centre/news-centre/article/?id=16312944&type=bsm
Ripley94, ref. Barnes-IBMer-Billionaires? Hold on to CNA, GSK & HLN?
Citi are not one of my favorite institutions, but for once it is nice to see a little reasoning behind a change in view rather than arbitrary cuts & raises as with LGEN last week.
Still difficult to monetize the reasoning though - so as ever taken with a large pinch of salt.
Citi upgrade is based not only on Blenrep’s under appreciated revenue potential of £2.5bn peak year sales but also the Zantac liability outlook RSV/Shingrix astute business development, increasingly positive ViiV outlook and GSK’s recent commercial and pipeline wins. As well as upgrading its rating from neutral to buy Citi upped its price target to 2100p from 1700p.
Clank/i would love to see this go back down to £13,so i can buy some more. Unfortunately i think those days are over. I can see this rerating to over £20 a share this year
More good news released today yet the share price is dropping again.
This is a very frustrating investment but am happy to hold as I have a lot of faith in this company and what they do
Hardman & Co
The demerger of Haleon has had little benefit on a more-focused GSK. Just after the demerger, the company was hit by the filing of litigation in the US claiming a causal association between ranitidine (Zantac) therapy and the development of cancer. In our opinion, there was little to support these claims, especially given the successful patient outcomes after billions of uses of the drug since launch. In 2023, GSK made a modest out-of-court settlement, but this did not trigger a re-rating back to the level seen prior to the claims first being made. At the end of the year, management indicated that it was going to embark on significant M&A activity in 2024, but this is expected to be in the form of licensing in drugs, rather than company takeovers, because of its current level of indebtedness. It will be interesting to see what the company does
Moderna’s shares were falling after the biotech revealed data that might hurt its vaccines competitive position.
In a note that appears to have shaken investor confidence in the product on Thursday TD Cowen analyst Tyler Van Buren wrote the data suggests the efficacy of Moderna’s RSV vaccine may fall off more quickly over time than those of its competitors.
It “could negatively affect mRNA-1345’s profile if confirmed with additional data” Van Buren wrote.
Moderna’s shares dropped 5.7% on Thursday and were down another 6.4% Friday.
Holding on for that sweet 17 before I finally say goodbye to the lion's share of my GSK holding. Here's hoping we hit that target pretty soon. All things considered it finally seems possible.